Details of the Drug

General Information of Drug (ID: DM6OKBJ)

• Drug Name: Ropidoxuridine
• Synonyms: IPdR; IPdR (LADD), Hana; IPdR, (LADD) SuperGen; 5-iodo-pyrimidinone-2'-deoxyribose; 5-iodo-pyrimidinone-2-deoxyribose (LADD), SuperGen

Indication

Disease Entry	ICD 11	Status	REF
Gastrointestinal cancer	2C11	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Drug Type: Small molecular drug
• Chemical Identifiers:
  Formula: C9H11IN2O4
  Canonical SMILES: C1C(C(OC1N2C=C(C=NC2=O)I)CO)O
  InChI: InChI=1S/C9H11IN2O4/c10-5-2-11-9(15)12(3-5)8-1-6(14)7(4-13)16-8/h2-3,6-8,13-14H,1,4H2/t6-,7+,8+/m0/s1
  InChIKey: XIJXHOVKJAXCGJ-XLPZGREQSA-N
• Cross-matching ID:
  PubChem CID: 9840777
  CAS Number: 93265-81-7
  UNII: 3HX21A3SQF
  DrugBank ID: DB06485
  TTD ID: D09WGH
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02381561) Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy. U.S. National Institutes of Health.